Combinatorial therapy to target melanoma resistant to immune checkpoint blockade
RNA-seq (gene expression) · human · 43 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Topic
- MelanomaThis series is part of our curated briefing on it.
- Samples
- 43 samples: 15 × Untreated MM vs 13 × PD1-Resistant MMGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE264375_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1102317 and SRA study SRP502818. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 28 samples.
How we read this: 2 replicated groups read from 43 sample titles; they account for 28 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM8217175 MM505-M10-Vehicle
- GSM8217176 MM505-M11-Cobimetinib + Regorafenib
- GSM8217177 MM505-M12-Vehicle
- GSM8217178 MM505-M2-Vehicle
- GSM8217179 MM505-M7-Cobimetinib + Regorafenib
- GSM8217180 MM505-M8-Cobimetinib + Regorafenib
- GSM8217181 MM337-M1-Vehicle
- GSM8217182 MM-337-M2-Cobimetinib + Regorafenib
- GSM8217183 MM337-M3-Cobimetinib + Regorafenib
- GSM8217184 MM337-M4-Cobimetinib + Regorafenib
- GSM8217185 MM337-M5-Vehicle
- GSM8217186 MM337-M6-Vehicle
- GSM8217187 MM337-M7-Cobimetinib + Regorafenib
- GSM8217188 MM337-M8-Vehicle
- GSM8217189 Untreated MM-178 Untreated MM
- GSM8217190 Untreated MM-224 Untreated MM
- GSM8217191 Untreated MM-348 Untreated MM
- GSM8217192 PD1-Resistant MM409 PD1-Resistant MM
- GSM8217193 Untreated MM-157 Untreated MM
- GSM8217194 Untreated MM-163 Untreated MM
- GSM8217195 Untreated MM-189 Untreated MM
- GSM8217196 Untreated MM-218 Untreated MM
- GSM8217197 Untreated MM-230 Untreated MM
- GSM8217198 Untreated MM-251 Untreated MM
- GSM8217199 PD1-Resistant MM-329 PD1-Resistant MM
- GSM8217200 PD1-Resistant MM406 PD1-Resistant MM
- GSM8217201 Untreated MM-179 Untreated MM
- GSM8217202 Untreated MM-195 Untreated MM
- GSM8217203 Untreated MM-206 Untreated MM
- GSM8217204 Untreated MM-219 Untreated MM
- GSM8217205 Untreated MM-325 Untreated MM
- GSM8217206 PD1-Resistant MM-337 PD1-Resistant MM
- GSM8217207 PD1-Resistant MM-386 PD1-Resistant MM
- GSM8217209 PD1-Resistant - MM_387-A7
- GSM8217210 Untreated MM-313 Untreated MM
- GSM8217211 PD1-Resistant MM-352 PD1-Resistant MM
- GSM8217212 PD1-Resistant MM-384 PD1-Resistant MM
- GSM8217214 PD1-Resistant MM-448 PD1-Resistant MM
- GSM8217215 PD1-Resistant MM395 PD1-Resistant MM
- GSM8217216 PD1-Resistant MM490 PD1-Resistant MM
+ 3 more — browse all 43 samples with per-sample file links →
- GSE91061 Molecular portraits of tumor mutational and micro-environmental sculpting by immune checkpoint blockade therapy 109 samples same disease briefing · shares checkpoint, blockade, therapy
- GSE100797 Mutational and neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma 25 samples same disease briefing · shares melanoma, therapy
- GSE123728 Clinical and Immunologic Activity of a Single Dose of Neoadjuvant PD-1 Blockade and Predictors of Clinical Outcomes in Resectable Melanoma 24 samples same disease briefing · shares melanoma, blockade
- GSE230489 RNA-sequencing of cutaneous melanoma and non-small cell lung cancer biopsies 38 samples same disease briefing · shares melanoma
- GSE130956 Investigation of ST8SIA1 expression in icaritin-treated and untreated melanoma cell lines 12 samples same disease briefing · shares melanoma
- GSE140150 A rare subpopulation of melanoma cells with low expression of metastasis suppressor NME1 has a neural crest-like phenotype and is highly metastatic in vivo 6 samples same disease briefing · shares melanoma
- GSE12391 Melanoma: comparison between common nevi, radial/vertical growth phase melanoma, metastases and dysplastic nevi 114 samples same disease briefing · shares melanoma
- GSE134459 Genome-wide maps of transcriptomic and epigenomic state in melanoma cell lines 73 samples same disease briefing · shares melanoma
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.